Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market: Epidemiology, Therapies, Companies, DelveInsight | AstraZeneca, Boehringer Ingelheim, Genentech/Roche, Eli Lilly, Hansoh Pharmaceutical, J&J Innovative Medicine, Pfizer, Cull

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) therapies, such as TAGRISSO, GILOTRIF/GIOTRIF, TARCEVA, RYBREVANT, VIZIMPRO, IRESSA, PORTRAZZA, Aumolertinib, Zipalertinib, Furmonertinib, BDTX-1535, Dato-DXd, BDTX-1535, JIN-A02, NX-019, STX-721, ORIC-11, and others, are expected to boost the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market in the upcoming years.

DelveInsight has launched a new report on "Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC), historical and forecasted epidemiology as well as the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market report @ https://www.delveinsight.com/report-store/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Report:

In 2023, the total market size for EGFR-mutant metastatic non-small cell lung cancer (mNSCLC) across the seven major markets (7MM) was approximately USD 4 billion. Biomarkers are increasingly shaping the NSCLC market landscape, with EGFR emerging as one of the most profitable segments. TAGRISSO remains a leading therapy in this area and currently holds a dominant market share. However, patient resistance to EGFR tyrosine kinase inhibitors (TKIs) is becoming more common, highlighting a significant unmet need in treating patients who relapse following TAGRISSO therapy.
On December 3, 2024, Merck announced that the FDA had granted Breakthrough Therapy designation to sacituzumab tirumotecan (sac-TMT) for patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) harboring EGFR mutations-specifically exon 19 deletions or exon 21 L858R-whose disease has progressed following treatment with tyrosine kinase inhibitors and platinum-based chemotherapy.
Among EGFR mNSCLC cases in the U.S. in 2023, exon 19 deletions accounted for the highest number, with nearly 14,300 cases. In July 2024, the European Union approved TAGRISSO (osimertinib) in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adults with advanced EGFR-mutated NSCLC.
Meanwhile, in June 2024, Janssen secured approval for a Type II variation of RYBREVANT, combining it with carboplatin and pemetrexed for first-line treatment of adult patients with advanced NSCLC harboring EGFR exon 20 insertion mutations. Johnson & Johnson is also transitioning RYBREVANT from intravenous infusion to a subcutaneous formulation, intensifying competition with AstraZeneca in the EGFR-mutant NSCLC space.
The exon 20 insertion mutation segment is the main focus for several emerging companies. Following the withdrawal of EXKIVITY from this space, RYBREVANT has taken a leading position. Companies such as Cullinan Oncology/Taiho Oncology, ArriVent BioPharma, and Dizal Pharmaceutical are also targeting this subsegment.
Next-generation EGFR inhibitors are under development by several biotech firms, including Black Diamond Therapeutics (BDTX-1535), J INTS BIO (JIN-A02), NALO Therapeutics (NX-019), and Scorpion Therapeutics (STX-721), among others.
The EGFR-NSCLC landscape is becoming increasingly crowded and competitive. Reflecting shifts in the external environment and recent clinical data, Blueprint Medicines exited the EGFR-NSCLC market on January 8, 2024, discontinuing both its BLU-945 and BLU-451 programs.
In 2023, there were approximately 524,000 new cases of non-small cell lung cancer (NSCLC) across the seven major markets (7MM), with this number expected to rise over the forecast period. In the United States alone, there were an estimated 202,500 new NSCLC cases in 2023.
Antibody-drug conjugates (ADCs) are also entering the EGFR-positive NSCLC market. Dato-DXd, alone or in combination with TAGRISSO, is currently under investigation in the TROPION-Lung14 (NCT06350097) and TROPION-Lung15 (NCT06417814) clinical trials for treating patients with EGFR-mutant locally advanced or metastatic NSCLC.
Key Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) companies such as AstraZeneca, Boehringer Ingelheim, Genentech/Roche, Eli Lilly, Hansoh Pharmaceutical, J&J Innovative Medicine, Pfizer, Cullinan Oncology, Taiho Pharmaceutical, ArriVent Biopharma, Black Diamond Therapeutics, Daiichi Sankyo, Black Diamond Therapeutic, J INTS BIO, NALO Therapeutics, Scorpion Therapeutics, ORIC Pharmaceuticals, and others are evaluating new drugs for Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) to improve the treatment landscape.
Promising Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) therapies include TAGRISSO, GILOTRIF/GIOTRIF, TARCEVA, RYBREVANT, VIZIMPRO, IRESSA, PORTRAZZA, Aumolertinib, Zipalertinib, Furmonertinib, BDTX-1535, Dato-DXd, BDTX-1535, JIN-A02, NX-019, STX-721, ORIC-11, and others.

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Overview

EGFR is a protein found in cells that plays a role in cell growth. When the gene responsible for EGFR mutates, it can lead to excessive cell growth and potentially result in cancer. EGFR mutations come in various forms, such as deletions, insertions, and point mutations. In diagnostic tests, individuals may be identified with common mutations like the EGFR exon 19 deletion or the L858R point mutation-both of which are usually managed with similar treatment approaches. However, among the EGFR mutations found in lung cancer, some rare variants require different treatment strategies. One notable example is EGFR exon 20 insertions, which do not typically respond to standard EGFR-targeted therapies known as tyrosine kinase inhibitors (TKIs).

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Outlook

Targeted therapies have significantly advanced the treatment of EGFR-mutant non-small cell lung cancer (NSCLC) over the past two decades, yet treatment options after EGFR TKI resistance remain limited. Common EGFR mutations like exon 19 deletions and exon 21 L858R are treated with first- (erlotinib, gefitinib), second- (afatinib, dacomitinib), and third-generation (osimertinib) TKIs, each offering different efficacy and safety profiles. Afatinib and osimertinib also show activity against some rare mutations, such as T790M and G719X.

Compared to chemotherapy, second-generation TKIs generally improve outcomes, and third-generation osimertinib is preferred after resistance develops, especially in T790M mutations. Despite improved efficacy, resistance remains a challenge, and no head-to-head trials have compared second- and third-generation TKIs directly.

New third-generation EGFR TKIs targeting exon 20 insertions-like furmonertinib (ArriVent), zipalertinib (Cullinan Oncology/Taiho), and sunvozertinib (Dizal)-are in development, aiming for a niche but growing market.

In 2023, the U.S. EGFR-mutant mNSCLC market was valued at around USD 2.19 billion and is projected to grow with new therapies and expanded indications. AstraZeneca's TAGRISSO leads globally, generating nearly USD 6 billion annually, and the company aims to further solidify its dominance through FLAURA2 trial expansion.

Chinese competitors are entering the market. Aumolertinib is approved in China, and its EMA review is based on Chinese trial data. Meanwhile, the FDA issued a complete response letter (CRL) in June 2024 for patritumab deruxtecan's accelerated approval in EGFR-mutated NSCLC, though global submissions will proceed using data from the HERTHENA-Lung02 study.

Discover how the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market is rising in the coming years @ https://www.delveinsight.com/sample-request/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Marketed Drugs
TAGRISSO: AstraZeneca
RYBREVANT: J&J Innovative Medicine

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Emerging Drugs
Aumolertinib: Hansoh Pharmaceutical
Zipalertinib: Cullinan Oncology/Taiho Pharmaceutical

Scope of the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Companies: AstraZeneca, Boehringer Ingelheim, Genentech/Roche, Eli Lilly, Hansoh Pharmaceutical, J&J Innovative Medicine, Pfizer, Cullinan Oncology, Taiho Pharmaceutical, ArriVent Biopharma, Black Diamond Therapeutics, Daiichi Sankyo, Black Diamond Therapeutic, J INTS BIO, NALO Therapeutics, Scorpion Therapeutics, ORIC Pharmaceuticals, and others
Key Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Therapies: TAGRISSO, GILOTRIF/GIOTRIF, TARCEVA, RYBREVANT, VIZIMPRO, IRESSA, PORTRAZZA, Aumolertinib, Zipalertinib, Furmonertinib, BDTX-1535, Dato-DXd, BDTX-1535, JIN-A02, NX-019, STX-721, ORIC-11, and others.
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Therapeutic Assessment: Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) current marketed and Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) emerging therapies
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Dynamics: Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market drivers and Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Unmet Needs, KOL's views, Analyst's views, Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Access and Reimbursement

To know what's more in our Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) report, visit https://www.delveinsight.com/report-store/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Report:
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market report covers a descriptive overview and comprehensive insight of the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Epidemiology and Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market report provides insights into the current and emerging therapies.
The Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market.

Got queries? Click here to know more about the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market Landscape https://www.delveinsight.com/sample-request/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Patient Share (%) Overview at a Glance
5. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Overview at a Glance
6. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Disease Background and Overview
7. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Epidemiology and Patient Population
8. Country-Specific Patient Population of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC)
9. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Current Treatment and Medical Practices
10. Unmet Needs
11. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Emerging Therapies
12. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Outlook
13. Country-Wise Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Outlook 2034 https://www.delveinsight.com/report-store/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Pipeline Insights, DelveInsight

"Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market. A detailed picture of the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) pipeline landscape is provided, which includes the disease overview and Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.